Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 2012. The report details specific share repurchase and cancellation activities executed on November 22, 2012, pursuant to shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on capital structure transactions:
- Shares Purchased: 800,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,339.0 pence per share; lowest was 1,333.5 pence per share.
- Treasury Shares Cancelled: 40,000,000 shares held as Treasury shares were cancelled.
- Remaining Treasury Holdings: 490,140,427 shares (9.07% of total issued share capital).
- Voting Rights Impact: Including unsettled purchases, Treasury shares represent 9.98% of total voting rights.
- Shares in Issue: 4,913,000,768 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of the company's share count through the cancellation of newly purchased shares and existing Treasury shares. The filing does not provide comparative financial data against prior periods to assess performance trends.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming adherence to the Financial Services Authority's Disclosure and Transparency Rules regarding share capital changes.
Investor Verification Checklist
- Verify the total number of shares in issue (4,913,000,768) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (490,140,427) and its percentage of total voting rights (9.98% including unsettled trades).
- Review the specific price range paid for the 800,000 shares repurchased on November 22, 2012.